The Global Heterozygous Familial Hypercholesterolemia Management Industry is poised for a remarkable surge, with a projected valuation of US$58.54 billion by 2033. This significant growth trajectory is fueled by a robust Compound Annual Growth Rate (CAGR) of 14.5% anticipated from 2023 to 2033. In fiscal year 2023, the market is expected to reach US$15.11 billion, …